Results 201 to 210 of about 59,676 (298)

Estradiol replacement attenuates alendronate‐associated adverse effects on alveolar bone repair in ovariectomized rats

open access: yesJournal of Periodontology, EarlyView.
Abstract Background Sodium alendronate (ALN) is widely used to treat postmenopausal osteoporosis, but both estrogen deficiency and antiresorptive therapy may impair alveolar bone repair after tooth extraction. A clinically relevant but insufficiently explored scenario involves estrogen‐deficient individuals receiving hormone replacement therapy (HRT ...
Pedro H. C. Isaias   +9 more
wiley   +1 more source

Dasatinib and quercetin prevent alveolar bone loss in aged mice

open access: yesJournal of Periodontology, EarlyView.
Abstract Background Recent findings have associated alveolar bone loss (ABL) with the presence of senescent cells. Aging and the accumulation of senescent cells are associated with a pro‐inflammatory environment which may exacerbate tissue damage.
Luisa S. Battistelli   +7 more
wiley   +1 more source

Adjunctive Botulinum Toxin Type A for Bruxism and Sweat‐Worsened Facial Blistering in Recessive Dystrophic Epidermolysis Bullosa: A Case Series

open access: yesJEADV Clinical Practice, EarlyView.
Capsule Summary Bruxism and sweat‐induced facial blisters can affect patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) quality of life (QoL). We present the outcomes of orofacial BTX‐A infiltrations to treat these conditions. Three patients with severe RDEB, bruxism and microstomia received BTX‐A infiltrations (50U‐100U) in masseters and ...
Susanne Krämer   +4 more
wiley   +1 more source

An Innovative Digital Teaching Method in Implantology

open access: yes
Journal of Dental Education, EarlyView.
María Gracia Ortega‐Moncayo   +3 more
wiley   +1 more source

Successful Use of Bimekizumab in Refractory Acute Generalised Exanthematous Pustulosis Triggered by Amoxicillin‐Clavulanate

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Acute generalised exanthematous pustulosis (AGEP) is a rare, acute neutrophilic dermatosis most commonly triggered by drugs, which typically resolves within 2 weeks following withdrawal of the causative agent. Topical and systemic corticosteroids remain the standard treatment.
Alexandra Junge   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy